Recursion Pharmaceuticals, Inc.(RXRX)Company Profile & BusinessNASDAQ
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Recursion Pharmaceuticals, Inc. (RXRX) between Jul 1, 2024 and Oct 6, 2026 consists of 207 total transactions. Among these, company executives and board members conducted 194 buys (totaling 15,331,765 shares) and 13 sells (totaling 379,345 shares). This activity resulted in a net change of 14,952,420 shares, reflecting net buying interest with an estimated net acquisitions value of $1.79B.
207 insider transactions found. Showing 10 of 207 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| Borgeson Blake | Director | -50,000 | $4.84 | Oct 6, 2026 |
| HERSHBERG ROBERT | Director | -25,000 | $5.00 | Oct 6, 2026 |
| KHAN NAJAT | Chief Executive Officer | 22,408 | $0.08 | Sep 8, 2026 |
| Khan Najat | CEO and President | -22,408 | $3.52 | Sep 8, 2026 |
| BORGESON BLAKE CHARLES | Director | 30,000 | $0.10 | Sep 1, 2026 |
| Borgeson Blake | Director | -30,000 | $3.34 | Sep 1, 2026 |
| BORGESON BLAKE CHARLES | Director | 30,000 | $0.10 | Aug 4, 2026 |
| Borgeson Blake | Director | -30,000 | $3.25 | Aug 4, 2026 |
| BORGESON BLAKE CHARLES | Director | 40,000 | $0.16 | Jul 7, 2026 |
| Borgeson Blake | Director | -40,000 | $3.96 | Jul 7, 2026 |
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.